AF
CBAY

Amalgamated Financial’s Cymabay Therapeutics CBAY Stock Holding History

Amalgamated Financial’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$26K Buy
+8,381
New +$26.4K ﹤0.01% 2669

Other funds holding CBAY

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return

Amalgamated Financial's CBAY Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Cymabay Therapeutics (CBAY) in Q1 2022: 8,381 shares worth $26K. The stake represents ﹤0.01% of the portfolio and ranks #2669 among its holdings.

118 funds tracked by Wall St. Rank hold CBAY as of Q1 2022.

  • Amalgamated Financial held 8,381 shares of Cymabay Therapeutics worth $26K as of Q1 2022.
  • Cymabay Therapeutics was a new Amalgamated Financial position in Q1 2022.
  • Cymabay Therapeutics made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2669 holding.
  • 118 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.